Page 115 - MBCA_FULL REPORT_FINAL_FOR_WEB

Study Drug(s) Target Biomarkers/ Combination Sponsor
Subtype
LJM716 ErB2 HER2+ Trastuzumab Novartis
TDM, protein-bound ERB2 HER2+ Methodist Hospital System
paclitaxel, lapatinib
Neratinib ErB2 HER2- Washington University,
St. Louis
212Pb-TCMC-Traztu- ErB2 and ER HER2+ Trastuzumab AREVA Med
zumab
AI, Lapatinib, trastu- ErB2 HER2+_Hormone+ National Cancer Institute
zumab
Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Vinorelbine Boehringer Ingelheim
Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Boehringer Ingelheim
Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Alone or with vinorel- Boehringer Ingelheim
bine
Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Boehringer Ingelheim
Neratinib vs. lapatinib ErB1/ErB2 HER2+ Capecitabine Puma Biotechnology
Active, not recruiting MM-121 ErB3 Hormone+_HER2- Merrimack Pharmaceuticals

IGF Receptors IGF-Methotrexate IGF All University Illinois/IGF Oncology
Hormone-mediated Endoxifen Estrogen Re- Hormone+ National Cancer Institute
ceptor
Z-endoxifen HCl Estrogen Re- Hormone+ National Cancer Institute
ceptor
Anostrazole + targeted Estrogen Re- Hormone+ Everolimus, sorafenib, MD Anderson Cancer Center
therapies ceptor erlotinib, fulvestrant,
or bevacizumab
ARN-810 Estrogen Re- Hormone+_HER2- Seragon Pharmaceuticals
ceptor
Enzalutamide Androgen TripleNegative Medivation/Astellas Pharma
Receptor
Enzalutamide Androgen Hormone+_HER2- Exemestane Medivation
Receptor
Enzalutamide Androgen All Astellas Pharma
receptor
Orteronel Androgen Androgen+ Sarah Cannon Research
receptor Institute
Orteronel CYP17A1/An- Hormone+ University of Wisconsin
drogen
Cabergoline Prolactin Re- Prolactin+ Northwestern University
ceptor
Exemestane/cyclophos- Estrogen Rec/ Hormone+_HER2- New York University
phamide ImmuneCells
Anastrazole vs. fulves- Estrogen Re- Hormone+
trant ceptor
Tamoxifen Estrogen Re- Hormone+ Biomarker analysis ECOG
ceptor CYP2D6
PTEN Mutation GSK2636771 PTEN Mutation TripleNegative GlaxoSmithKline
Other Tetrathiomolybdate Copper All Weill Cornell Medical College
MORAb-066 TissueFactor All Morphotek
antigen
ENMD-2076 Unspecified TripleNegative EntreMed
tyrosine kinase
Dovitinib FGFR HER2+ Novartis/MD Anderson
Cancer Center
Active, not recruiting Dovitinib FGFR3 Hormone+_HER2- Aromatase inhibitor Georgetown University